期刊文献+

依卡倍特钠对反流性食管炎大鼠食管黏膜的保护作用及可能机制 被引量:4

Esophageal mucosa protective effects and its mechanism of Ecabet sodium in rat reflux esophagitis
下载PDF
导出
摘要 目的:探讨依卡倍特钠(ES)对反流性食管炎大鼠食管黏膜病变的保护作用及其机制。方法:采用食管十二指肠吻合术建立大鼠RE模型,进行药物干预。HE染色检测各组大鼠食管黏膜损伤情况;ELISA检测各组大鼠血清炎症因子水平;Real-time PCR检测食管内TNFα、IL-1、Cox2mRNA表达;Western blot检测食管内ERK及P38通路活化。结果:ES低、中、高浓度干预不同程度缓解了食管黏膜病变,降低血清中TNFα、IL-1β水平及食管中TNFα、IL-1、Cox2表达(P<0.05),抑制ERK及P38通路的异常活化(P<0.05)。结论:ES通过抑制MAPK信号通路抑制TNFα、IL-1、Cox2的表达,影响炎症因子的释放和炎症发生,从而缓解食管黏膜病变。 Objective:To inquire into the esophageal mucosa protective effects of Ecabet sodium(ES)in rat reflux esophagitis(RE)and its possible mechanism.Methods:The operation of end-to-side anastomosis of the esophagus and duodenum was performed to establish rat RE model.Esophageal mucosa lesion was examined by HE stain.The level of TNFαand IL-1βin sera was determined by ELISA.The level of TNFα,IL-1and Cox2 in esophageal tissues were detected by Real-time PCR.The activation of ERK and P38 was detected by western blot.Results:Low,middle and high concentration ES intervention showed different levels of alleviation of esophageal mucosa disease,decreased the level of TNFαand IL-1βin serum and TNFα,IL-1,Cox2 in esophagus(P<0.05).Otherwise,ES inhibited the abnormality activation of ERK and P38(P<0.05).Conclusion:By inhibiting the MAPK signaling pathways and suppress the expression of TNFα,IL-1and Cox2,ES thereby inhibits the release of inflammatory cytokines and inflammation,and as a result reduces esophageal mucosal lesions in RE model.
出处 《陕西医学杂志》 CAS 2016年第11期1452-1455,共4页 Shaanxi Medical Journal
关键词 食管炎/药物疗法 黏膜保护剂/药理学 胃食管反流 @MAPK 信号通路 大鼠 Ecabet sodium Reflux Esophagitis/drug therapy Demullents/pharmacology Gastroesophageal reflux @MAPK signaling pathway Rats
  • 相关文献

参考文献2

二级参考文献58

  • 1杨艳,李耀芳.质子泵抑制剂的不良反应与药物相互作用[J].深圳中西医结合杂志,2007,17(5):324-327. 被引量:21
  • 2蒋义贵,尤丽财,张生君,等.黛力新治疗伴有焦虑及抑郁状态的非糜烂性胃食管反流病60例[J].中国药物经济学,2014,(1): 219-220.
  • 3Peura DA,Pilmer B,Hunt B,et al.Distinguishing the impact of dexlansoprazole on hearburn vs.regurgitation in patients with gastro-oesophageal reflux disease[J].Aliment Pharmacol Ther,2013,38(10):1303-1311.
  • 4Baker LH,Ljeberman D,Oehlke M.Psychological distress in patients witll gastroesophageal reflux disease[J].Am J Gastroenterol,2008,90(10):1797-1803.
  • 5Herregods TV, Bredenoord AJ, Smout AJ. Pathophysiology ofgastroesophageal reflux disease: new understanding in a new era.Neurogastroenterol Motil 2015; 27: 1202-1213 [PMID: 26053301DOI: 10.1111/nmo.12611].
  • 6Hummel K, Richards W. Endoscopic treatment of gastroesophagealreflux disease. Surg Clin North Am 2015; 95: 653-667[PMID: 25965137 DOI: 10.1016/j.suc.2015.02.016].
  • 7Yates RB, Oelschlager BK. Surgical treatment of gastroesophagealreflux disease. Surg Clin North Am 2015; 95: 527-553 [PMID:25965128 DOI: 10.1016/j.suc.2015.02.007].
  • 8Katz PO, Gerson LB, Vela MF. Guidelines for the diagnosis andmanagement of gastroesophageal reflux disease. Am J Gastroenterol2013; 108: 308-328; quiz 329 [PMID: 23419381 DOI: 10.1038/ajg.2012.444].
  • 9Kleiman DA, Beninato T, Bosworth BP, Brunaud L, CiecieregaT, Crawford CV, Turner BG, Fahey TJ, Zarnegar R. Earlyreferral for esophageal pH monitoring is more cost-effective thanprolonged empiric trials of proton-pump inhibitors for suspectedgastroesophageal reflux disease. J Gastrointest Surg 2014; 18:26-33; discussion 33-34 [PMID: 24214090 DOI: 10.1007/s11605-013-2327-x].
  • 10Ware JE, Sherbourne CD. The MOS 36-item short-form healthsurvey (SF-36). I. Conceptual framework and item selection. MedCare 1992; 30: 473-483 [PMID: 1593914 DOI: 10.1097/00005650-199206000-00002].

共引文献9

同被引文献27

引证文献4

二级引证文献66

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部